Pre‐exposure prophylaxis to reduce HIV infection in the UK

Abstract

Recent research has estimated that pre‐exposure prophylaxis (PrEP) using the antiretroviral therapy Truvada (tenofovir disoproxil/emtricitabine) in men who have sex with men could prevent thousands of new HIV infections in the UK by the end of the decade. However, the treatment has not yet been made available on the NHS for this indication.